Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
doi: 10.1016/j.jdiacomp.2019.107520 [DOI] [PubMed] [Google Scholar] 18.Thangavelu T, Lyden E, Shivaswamy V
Executive Summary Quick Insight: The GLP-1 Weight Loss Drug Market is on track to more than double to USD 192 billion by 2035 , driven by explosive patient demand for injectable and oral incretin therapies, multi-indication label expansion beyond obesity into cardiovascular protection and metabolic disease management, a robust late-stage pipeline of next-generation triple agonists, and unprecedented payer engagement transforming obesity into a fully reimbursable chronic disease requiring long-term pharmacological management
Plus, it supports blood sugar regulation and may promote satiety
While this study is small, we provide essential preliminary data (e.g., effect sizes) for the design and development of larger randomized control trials testing the effectiveness of GLP-1RAs on reductions in alcohol use
DOES FIT ON SUPPORT REALLY WORK
